Thrombosis research最新文献

{"title":"Characteristics and outcomes of venous thromboembolism-related litigation in orthopaedic surgery","authors":"Haad A. Arif ,&nbsp;Andrew Miner ,&nbsp;Simon T. Moore ,&nbsp;Gavin LeBrun ,&nbsp;Abbad Sultan ,&nbsp;Joseph G. Elsissy","doi":"10.1016/j.thromres.2025.109443","DOIUrl":"10.1016/j.thromres.2025.109443","url":null,"abstract":"<div><h3>Background</h3><div>Venous thromboembolism (VTE) is a considerable source of morbidity, mortality, and economic burden within orthopaedic surgery. Our study aimed to analyze the characteristics and reasons for lawsuits pertaining to VTE levied against orthopaedic surgeons.</div></div><div><h3>Methods</h3><div>The Westlaw database was queried for cases filed between 1980 and 2023 against orthopaedic surgeons involving VTE, using the search terms “orthopaedic”, “blood clot,” “deep vein thrombosis,” “venous thromboembolism,” and “pulmonary embolism.”</div></div><div><h3>Results</h3><div>A total of 122 out of 371 cases were selected for inclusion in this study. A defendant verdict was reached in 84 (69 %) cases and a plaintiff-verdict in 23 (19 %) cases. Fifteen (12 %) cases were settled. The mean indemnity payment and settlement award were $2.39 million and $662 thousand, respectively. Discontinuation or failure to initiate post-discharge anticoagulation therapy was cited in 25 % of cases. The most common basis of litigation was diagnostic/therapeutic delay (42 %) and inadequate VTE prophylaxis (39 %). Death was the most frequently reported complication (64 %). Patient-reported pain and suffering was associated with a defendant verdict (p = 0.0204). The choice of anticoagulant was not found to increase the risk of a plaintiff-favorable verdict (p = 0.6754).</div></div><div><h3>Conclusions</h3><div>Malpractice cases related to VTE in orthopaedic surgery are associated with substantial financial liability and arise in the setting of delayed diagnosis of VTE or failure to initiate thromboprophylaxis. Current medicolegal trends do not indicate a preference for any specific VTE prophylactic agent. Implementing a systems-based strategy to optimize transitions of care may help reduce both the incidence of VTE and the associated risk of litigation.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"254 ","pages":"Article 109443"},"PeriodicalIF":3.4,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144922543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antibodies to oxidation-specific epitopes characterize hemodialysis patients protected from cardiovascular events","authors":"Rafaela Vostatek ,&nbsp;Taras Afonyushkin ,&nbsp;Maria Ozsvar Kozma ,&nbsp;Sabine Schmaldienst ,&nbsp;Matthias Lorenz ,&nbsp;Renate Klauser-Braun ,&nbsp;Ingrid Pabinger ,&nbsp;Marcus Säemann ,&nbsp;Cihan Ay ,&nbsp;Christoph J. Binder ,&nbsp;Oliver Königsbrügge","doi":"10.1016/j.thromres.2025.109431","DOIUrl":"10.1016/j.thromres.2025.109431","url":null,"abstract":"<div><h3>Background</h3><div>Despite the high risk of cardiovascular disease (CVD) in patients on hemodialysis (HD), some appear protected from CVD-associated mortality and survive long-term on HD. The immune system can recognize oxidation-specific epitopes (OSEs) and create antibodies with pro- or antithrombotic properties. This study aimed to elucidate the role of natural antibodies against OSEs in patients on hemodialysis (HD) and their association with cardiovascular outcomes.</div></div><div><h3>Methods</h3><div>Serum levels of IgM and IgG autoantibodies to OSEs (including CuOx-LDL, MDA-LDL, and MAA-BSA) were measured using an ELISA assay in a prospective population-based cohort study of prevalent HD patients. The risk for the occurrence of the 3P-MACE outcome (myocardial infarction, ischemic stroke, and cardiovascular death) with the association of antibodies against OSEs was statistically analyzed in a competing risk framework.</div></div><div><h3>Results</h3><div>In our study of 595 patients with ESKD (236 (37 %) women, median age: 67 (25th to 75th percentile 55–75) years); 54 patients were long-term survivors (&gt;10 years on HD). There was no association between IgM and IgG antibodies to OSEs with the risk of 3P-MACE occurrence after adjusting for age, atrial fibrillation, stroke, and coronary heart disease. However, long-term survivors on HD, exhibited higher levels of antibodies to OSEs compared to other patients and lower risk of 3P-MACE (IgG MAA-BSA median 97,663.83 in long-term survivors versus 70,833.50 RLU rest of the cohort, <em>p</em> = 0.001).</div></div><div><h3>Conclusion</h3><div>Natural autoantibodies against OSEs were not associated with the overall risk of 3P-MACE in this cohort of HD patients. However, we found that long-term survivors had higher levels of natural autoantibodies against OSEs.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"254 ","pages":"Article 109431"},"PeriodicalIF":3.4,"publicationDate":"2025-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144860467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Leukadherin-1 mitigates disseminated intravascular coagulation in acute pancreatitis by suppressing necroptosis","authors":"Nigel Mackman ,&nbsp;Megan V. Perkins ,&nbsp;Sierra Archibald ,&nbsp;Ana T.A. Sachetto","doi":"10.1016/j.thromres.2025.109429","DOIUrl":"10.1016/j.thromres.2025.109429","url":null,"abstract":"","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"254 ","pages":"Article 109429"},"PeriodicalIF":3.4,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144880111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thromboelastographic assessment of hypofibrinolysis in stored plasma samples: A novel spike-in method","authors":"Stefanie Hammer ,&nbsp;Leah Heuer ,&nbsp;Günalp Uzun ,&nbsp;Tamam Bakchoul ,&nbsp;Karina Althaus","doi":"10.1016/j.thromres.2025.109430","DOIUrl":"10.1016/j.thromres.2025.109430","url":null,"abstract":"<div><h3>Introduction</h3><div>Congenital or acquired dysregulation of fibrinolytic system can lead to bleeding (hyperfibrinolysis) or thrombosis (hypofibrinolysis), with increased risk for multi-organ failure. Standard clotting-based assays provide limited insight into fibrinolytic status. In contrast, thromboelastography (TEG), a whole blood assay, offers a comprehensive assessment of the coagulation and fibrinolytic systems. While freezing plasma samples enables later investigation of plasmatic coagulation factors, viscoelastic testing (VT) requires immediate testing. In this study, we evaluated a new diagnostic approach to assess fibrinolysis in frozen plasma samples spiked into healthy whole blood using VT.</div></div><div><h3>Methods</h3><div>Citrated whole blood and corresponding frozen platelet-poor plasma (PPP) samples from patients with hypofibrinolytic disorders were analyzed using thromboelastography (TEG). The spike-in method involved reconstituting patient-derived frozen PPP into plasma-depleted blood from healthy subjects. In addition, the Lysis Timer®, a global fibrinolysis capacity assay, was used to assess fibrinolysis in plasma samples.</div></div><div><h3>Results</h3><div>The validation study showed strong correlation between lysis time (LT) of VT in healthy whole blood and spiked samples (r = 0.6720, p = 0.0012). Hypofibrinolytic patients exhibited significantly increased LT in the tissue plasminogen activator-test of VT (LT-TPA) when their PPP was spiked into healthy whole blood, confirming hypofibrinolytic activity (LT-TPA whole blood of healthy donors vs. spike-in with patients, PPP: 165.7 ± 16.6 s vs. 218.3 ± 39.6 s, p &lt; 0.0001). The Lysis Timer assay supported these findings, suggesting a plasmatic factor rather than cell-derived resistance to fibrinolysis.</div></div><div><h3>Conclusion</h3><div>The spike-in approach can be used to retrospectively detect hypofibrinolysis in frozen samples using TEG. This method is particularly useful for clinical studies when immediate VT is not available.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"254 ","pages":"Article 109430"},"PeriodicalIF":3.4,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144917558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of interleukin-10 gene variants in inhibitor development in hemophilia: A meta-analysis","authors":"Alessandra Faustino da Conceição Bezerra ,&nbsp;Yanka Karolinna Batista-Rodrigues ,&nbsp;Suely Meireles Rezende ,&nbsp;Renan Pedra de Souza","doi":"10.1016/j.thromres.2025.109427","DOIUrl":"10.1016/j.thromres.2025.109427","url":null,"abstract":"<div><h3>Background</h3><div>A major therapeutic challenge in hemophilia is the development of inhibitors that neutralize replacement therapies. Interleukin-10 (IL-10), an anti-inflammatory cytokine, regulates immune responses and influences antibody production, suggesting a potential role in inhibitor formation.</div></div><div><h3>Objectives</h3><div>This systematic review aimed to investigate the association of <em>IL-10</em> polymorphism with inhibitor formation in patients with hemophilia.</div></div><div><h3>Methods</h3><div>Following PRISMA guidelines, the study was registered in PROSPERO (CRD42024590045). Genetic studies on <em>IL-10</em> polymorphisms and inhibitors were included, while case reports, reviews, and animal studies were excluded. A comprehensive search was conducted in PubMed and Scielo, covering records up to January 27, 2025. Methodological quality was assessed using Q-genie, and a meta-analysis was performed for polymorphisms with data from at least three studies, using the Mantel-Haenszel method.</div></div><div><h3>Results</h3><div>Of 105 screened studies, 19 were included in the systematic review and 12 in the meta-analysis. No significant association was found between <em>IL-10</em> polymorphisms (rs1800896, rs1800871, rs1800872) and inhibitor formation. In a subgroup analysis, the T-rs1800871 and A-rs1800872 recessive models were associated with protection against inhibitor development in subjects with severe hemophilia A.</div></div><div><h3>Conclusion</h3><div>These findings suggest that IL-10 may not have a central role in the genetic predisposition to inhibitor formation. However, the significant association observed in the severe hemophilia A subgroup emphasizes the need for further investigation into the role of IL-10 in immune tolerance.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"253 ","pages":"Article 109427"},"PeriodicalIF":3.4,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144830891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thrombectomy in high-risk pulmonary embolism – device versus thrombolysis: rationale and design of the TORPEDO-NL investigator-initiated, academically-sponsored, multicenter, open-label randomized controlled trial","authors":"W.J.E. Stenger ,&nbsp;C.A. den Uil ,&nbsp;W.J.R. Rietdijk ,&nbsp;I. Al Amri ,&nbsp;J.M. Montero-Cabezas ,&nbsp;C.V. Elzo Kraemer ,&nbsp;T.E. van Mens ,&nbsp;C.L. Meuwese ,&nbsp;N.M.D.A. van Mieghem ,&nbsp;M.N. Lauw ,&nbsp;L.M. van den Toorn ,&nbsp;S. Levolger ,&nbsp;K.M. van de Luijtgaarden ,&nbsp;R.A. Sprenger ,&nbsp;J.M. van Dongen ,&nbsp;F. Imani ,&nbsp;M. Meuwissen ,&nbsp;K.M. Kant ,&nbsp;R.A.H.M. Aarts ,&nbsp;K. Winckers ,&nbsp;J. Jongkind","doi":"10.1016/j.thromres.2025.109420","DOIUrl":"10.1016/j.thromres.2025.109420","url":null,"abstract":"<div><h3>Background</h3><div>Catheter-directed thrombectomy (CDT) is a promising alternative to full dose thrombolysis in patients with acute high-risk pulmonary embolism (PE), expected to have a more direct effect on pulmonary artery clot burden and a better safety profile. Randomized trials evaluating the safety and efficacy of CDT in high-risk patients are currently unavailable.</div></div><div><h3>Methods and results</h3><div>The TORPEDO-NL study is an investigator-initiated, publicly-funded, multicenter, open-label randomized controlled trial designed to evaluate the superiority of CDT over systemic thrombolysis in patients with high-risk PE. Adults with: 1) confirmed acute PE, 2) a high risk for mortality, and 3) CDT available and technically feasible, will be randomized 2:1 to CDT versus systemic thrombolysis. The primary outcome is the composite incidence of all-cause mortality, treatment failure, major bleeding, and all-cause stroke at day 30. Secondary outcomes include desirability of outcome ranking (DOOR) at day 7, length of hospital stay, patient-reported outcomes including quality of life and symptom burden, functional recovery, and 1-year cost-effectiveness. The trial anticipates recruiting 111 patients and is funded by the The Netherlands Health Care Institute, The Netherlands Organization for Health Research and Development, the Dutch Heart Foundation, and unrestricted grants from Penumbra Inc. and Inari Medical. <span><span>ClinicalTrials.gov</span><svg><path></path></svg></span> number, <span><span>NCT06833827</span><svg><path></path></svg></span>.</div></div><div><h3>Conclusions</h3><div>TORPEDO-NL is the first publicly-funded randomized trial to investigate the effect of CDT treatment specifically in high-risk PE patients. The trial is anticipated to play an important role in revising recommendations for high-risk PE treatment in international guidelines.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"255 ","pages":"Article 109420"},"PeriodicalIF":3.4,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145201345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of thrombocytopenia in patients with cancer-associated isolated distal deep vein thrombosis treated with edoxaban for 12 months versus 3 months: Insights from the ONCO DVT study","authors":"Yutaro Miyoshi ,&nbsp;Yugo Yamashita ,&nbsp;Takeshi Morimoto ,&nbsp;Nao Muraoka ,&nbsp;Michihisa Umetsu ,&nbsp;Yuji Nishimoto ,&nbsp;Takuma Takada ,&nbsp;Yoshito Ogihara ,&nbsp;Tatsuya Nishikawa ,&nbsp;Nobutaka Ikeda ,&nbsp;Kazunori Otsui ,&nbsp;Daisuke Sueta ,&nbsp;Yukari Tsubata ,&nbsp;Masaaki Shoji ,&nbsp;Ayumi Shikama ,&nbsp;Yutaka Hosoi ,&nbsp;Yasuhiro Tanabe ,&nbsp;Ryuki Chatani ,&nbsp;Kengo Tsukahara ,&nbsp;Naohiko Nakanishi ,&nbsp;Takeshi Kimura","doi":"10.1016/j.thromres.2025.109419","DOIUrl":"10.1016/j.thromres.2025.109419","url":null,"abstract":"","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"253 ","pages":"Article 109419"},"PeriodicalIF":3.4,"publicationDate":"2025-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144830892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A real-world pharmacovigilance analysis of the FDA adverse event reporting system database for emicizumab","authors":"Tianyi Li ,&nbsp;Dongping Huang ,&nbsp;Yizhi Jiang","doi":"10.1016/j.thromres.2025.109422","DOIUrl":"10.1016/j.thromres.2025.109422","url":null,"abstract":"<div><h3>Background and objectives</h3><div>Emicizumab has fundamentally changed the clinical management of hemophilia A. Despite its benefits, concerns about adverse events (AEs) have risen. This retrospective study used disproportionality analysis of FAERS data from 2017 to 2023 to examine AEs associated with emicizumab, either alone or in combination with activated prothrombin complex concentrate (aPCC) or recombinant activated factor VII (rFVIIa), as well as the timing of these AEs.</div></div><div><h3>Methods</h3><div>Established algorithms (ROR, PRR, BCPNN, and MGPS) were used to assess correlations and calibrated <em>p</em>-values.</div></div><div><h3>Results</h3><div>Based on 1198 AEs, we identified 126 cases that met four algorithmic criteria. AEs associated with emicizumab included primarily joint pain and injection site reactions (ISRs), consistent with the drug label. Additionally, we observed thrombotic events related to emicizumab's black box warning. Specifically, we found that emicizumab poses increased risks of thrombosis when used in conjunction with aPCC or rFVIIa to treat breakthrough bleeds. After excluding reports related to the progression of hemophilia, we obtained 850 AEs with reported onset times. The median onset time for AEs was 106 days, with 46.59 % occurring within the first 90 days of emicizumab treatment.</div></div><div><h3>Conclusion</h3><div>Our study demonstrates the importance of early monitoring and interventions to minimize AEs and alleviate patient suffering.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"254 ","pages":"Article 109422"},"PeriodicalIF":3.4,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144863949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between the PROTECHT score and mortality in patients with cancer: results from a prospective cohort study","authors":"Yara Abrão Vasconcelos Vivas ,&nbsp;Ester Martins Camillozzi Medina ,&nbsp;Eliabe Silva de Abreu ,&nbsp;Dário Alves da Silva Costa ,&nbsp;Suely Meireles Rezende ,&nbsp;Daniel Dias Ribeiro","doi":"10.1016/j.thromres.2025.109421","DOIUrl":"10.1016/j.thromres.2025.109421","url":null,"abstract":"","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"253 ","pages":"Article 109421"},"PeriodicalIF":3.4,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144779370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Iron deficiency anemia as a risk factor associated with stroke and cerebral venous thrombosis in children and adults - a systematic review","authors":"Mai Erritzøe-Jervild ,&nbsp;Christina Kruuse ,&nbsp;Arkadiusz Weglewski ,&nbsp;Nina Vindegaard Sørensen","doi":"10.1016/j.thromres.2025.109425","DOIUrl":"10.1016/j.thromres.2025.109425","url":null,"abstract":"<div><h3>Objectives</h3><div>Iron deficiency anemia (IDA) might have an association with stroke and cerebral venous thrombosis (CVT), but no systematic evaluation of the literature has been conducted to support this. The aim of this systematic review was to assess IDA as a potential risk factor for stroke and CVT by analyzing all papers published on IDA-related strokes and CVTs.</div></div><div><h3>Methods and materials</h3><div>A systematic review by use of the databases EMBASE and Pubmed. The study was registered at PROSPERO before data collection and PRISMA guidelines were followed. Case reports and studies on IDA as a risk factor for stroke and CVT were included with no limitations, though papers not written in English were excluded.</div></div><div><h3>Results</h3><div>In total, 2202 papers were identified of which 87 were included, hereof 71 case reports or -series, 16 observational studies, and two papers comprising both categories. The 18 observational studies indicated an association of IDA with stroke, however, were limited by sample size. The case reports included 52 adult and 53 pediatric cases. Females accounted for 65.7 % of all reported cases. The median age of all included cases was 17.0 years (range 0.4–70.0). Mean hemoglobin was 6.7 g/dL (SD 2.3), and mean ferritin was 7 ng/mL (SD 6).</div></div><div><h3>Conclusion</h3><div>IDA is an under-investigated potential risk factor for stroke and CVT—especially in children and younger adults. Large-scale, longitudinal studies are needed to confirm IDA as a stroke and CVT risk factor and identify specific subgroups at a higher risk of stroke and CVT associated with IDA.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"253 ","pages":"Article 109425"},"PeriodicalIF":3.4,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144852583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}